RATIONALE: Arginine methylation by protein N-arginine methyltransferases (PRMTs) is an important posttranslational modification in the regulation of protein signaling. PRMT2 contains a highly conserved catalytic Ado-Met binding domain, but the enzymatic function of PRMT2 with respect to methylation is unknown. The JAK-STAT pathway is proposed to be regulated through direct arginine methylation of STAT transcription factors, and STAT3 signaling is known to be required for leptin regulation of energy balance. OBJECTIVE: To identify the potential role of STAT3 arginine methylation by PRMT2 in the regulation of leptin signaling and energy homeostasis. METHODS AND RESULTS: We identified that PRMT2(-/-) mice are hypophagic, lean, and have significantly reduced serum leptin levels. This lean phenotype is accompanied by resistance to food-dependent obesity and an increased sensitivity to exogenous leptin administration. PRMT2 colocalizes with STAT3 in hypothalamic nuclei, where it binds and methylates STAT3 through its Ado-Met binding domain. In vitro studies further clarified that the Ado-Met binding domain of PRMT2 induces STAT3 methylation at the Arg31 residue. Absence of PRMT2 results in decreased methylation and prolonged tyrosine phosphorylation of hypothalamic STAT3, which was associated with increased expression of hypothalamic proopiomelanocortin following leptin stimulation. CONCLUSIONS: These data elucidate a molecular pathway that directly links arginine methylation of STAT3 by PRMT2 to the regulation of leptin signaling, suggesting a potential role for PRMT2 antagonism in the treatment of obesity and obesity-related syndromes.
RATIONALE: Arginine methylation by protein N-arginine methyltransferases (PRMTs) is an important posttranslational modification in the regulation of protein signaling. PRMT2 contains a highly conserved catalytic Ado-Met binding domain, but the enzymatic function of PRMT2 with respect to methylation is unknown. The JAK-STAT pathway is proposed to be regulated through direct arginine methylation of STAT transcription factors, and STAT3 signaling is known to be required for leptin regulation of energy balance. OBJECTIVE: To identify the potential role of STAT3arginine methylation by PRMT2 in the regulation of leptin signaling and energy homeostasis. METHODS AND RESULTS: We identified that PRMT2(-/-) mice are hypophagic, lean, and have significantly reduced serum leptin levels. This lean phenotype is accompanied by resistance to food-dependent obesity and an increased sensitivity to exogenous leptin administration. PRMT2 colocalizes with STAT3 in hypothalamic nuclei, where it binds and methylates STAT3 through its Ado-Met binding domain. In vitro studies further clarified that the Ado-Met binding domain of PRMT2 induces STAT3 methylation at the Arg31 residue. Absence of PRMT2 results in decreased methylation and prolonged tyrosine phosphorylation of hypothalamic STAT3, which was associated with increased expression of hypothalamic proopiomelanocortin following leptin stimulation. CONCLUSIONS: These data elucidate a molecular pathway that directly links arginine methylation of STAT3 by PRMT2 to the regulation of leptin signaling, suggesting a potential role for PRMT2 antagonism in the treatment of obesity and obesity-related syndromes.
Authors: M Elchebly; P Payette; E Michaliszyn; W Cromlish; S Collins; A L Loy; D Normandin; A Cheng; J Himms-Hagen; C C Chan; C Ramachandran; M J Gresser; M L Tremblay; B P Kennedy Journal: Science Date: 1999-03-05 Impact factor: 47.728
Authors: B G Challis; A P Coll; G S H Yeo; S B Pinnock; S L Dickson; R R Thresher; J Dixon; D Zahn; J J Rochford; A White; R L Oliver; G Millington; S A Aparicio; W H Colledge; A P Russ; M B Carlton; S O'Rahilly Journal: Proc Natl Acad Sci U S A Date: 2004-03-15 Impact factor: 11.205
Authors: C F Elias; C Lee; J Kelly; C Aschkenasi; R S Ahima; P R Couceyro; M J Kuhar; C B Saper; J K Elmquist Journal: Neuron Date: 1998-12 Impact factor: 17.173
Authors: Mei-Ling Yang; Hester A Doyle; Steven G Clarke; Kevan C Herold; Mark J Mamula Journal: Antioxid Redox Signal Date: 2017-12-11 Impact factor: 8.401
Authors: Tae Gyu Oh; Peter Bailey; Eloise Dray; Aaron G Smith; Joel Goode; Natalie Eriksson; John W Funder; Peter J Fuller; Evan R Simpson; Wayne D Tilley; Peter J Leedman; Christine L Clarke; Sean Grimmond; Dennis H Dowhan; George E O Muscat Journal: Mol Endocrinol Date: 2014-06-09
Authors: Matthew S Waitkus; Unni M Chandrasekharan; Belinda Willard; Thomas L Tee; Jason K Hsieh; Christopher G Przybycin; Brian I Rini; Paul E Dicorleto Journal: Mol Cell Biol Date: 2014-03-10 Impact factor: 4.272
Authors: Elizabeth P Sampaio; Amy P Hsu; Joseph Pechacek; Hannelore I Bax; Dalton L Dias; Michelle L Paulson; Prabha Chandrasekaran; Lindsey B Rosen; Daniel S Carvalho; Li Ding; Donald C Vinh; Sarah K Browne; Shrimati Datta; Joshua D Milner; Douglas B Kuhns; Debra A Long Priel; Mohammed A Sadat; Michael Shiloh; Brendan De Marco; Michael Alvares; Jason W Gillman; Vivek Ramarathnam; Maite de la Morena; Liliana Bezrodnik; Ileana Moreira; Gulbu Uzel; Daniel Johnson; Christine Spalding; Christa S Zerbe; Henry Wiley; David E Greenberg; Susan E Hoover; Sergio D Rosenzweig; John N Galgiani; Steven M Holland Journal: J Allergy Clin Immunol Date: 2013-03-28 Impact factor: 10.793
Authors: Mynol I Vhuiyan; Magnolia L Pak; Margaret A Park; Dylan Thomas; Ted M Lakowski; Charles E Chalfant; Adam Frankel Journal: J Biochem Date: 2017-07-01 Impact factor: 3.387